Boehringer Ingelheim

News

Boehringer looks to enhance COPD care with new registry

Boehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience in COPD), to better understan

News

AbbVie gets crucial US approval for psoriasis drug Skyrizi

With one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Skyrizi approved in the US.

News

BI chief "regrets" Brexit, but continues to invest in UK

The head of Germany’s Boehringer Ingelheim has said that he “regrets” Brexit, but reassured patients in the country that the company still regards it as an important market for new drug lau

News

Boehringer's blockbuster Spiriva under pressure, profits dow...

Boehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, as price competition began to affect its biggest selling drug Spiriva.<

News

Boehringer files for new rare disease use for nintedanib in ...

Boehringer Ingelheim has filed for a new use for its lung drug nintedanib in the US and Europe, bidding to add the rare disease systemic sclerosis to the existing indication for idiopathic

News

AZ backs diabetes drug Farxiga with new cardio analysis

AstraZeneca continues to make the case for its Farxiga diabetes drug, highlighting a cardiology analysis that it hopes will convince more doctors to prescribe it in a highly competitive mar

Boehringer looks to enhance COPD care with new registry

AbbVie gets crucial US approval for psoriasis drug Skyrizi

BI chief "regrets" Brexit, but continues to invest in UK

Boehringer's blockbuster Spiriva under pressure, profits dow...

Boehringer files for new rare disease use for nintedanib in ...

AZ backs diabetes drug Farxiga with new cardio analysis

Immunovant's thyroid eye disease drug flunks pivotal trials

Using AI-driven synthetic personas to take your insights fur...

Boehringer Ingelheim

Editor's Picks